Der Gynäkologe

, Volume 39, Issue 4, pp 327–331


Ist die intraperitoneale Therapie wirklich neuer Standard?
  • A. du Bois
  • B. Schmalfeldt
  • W. Meier
  • J. Sehouli
  • J. Pfisterer
  • die AGO Studiengruppe Ovarialkarzinom (AGO-OVAR) und die Nordostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO)
Gynäkologie aktuell

Ovarian cancer

Is intraperitoneal therapy really the new standard?


  1. 1.
    Alberts DS, Liu PY, Hannigan EV et al. (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950–1955CrossRefPubMedGoogle Scholar
  2. 2.
    Armstrong D, Bundy B, WenzelL et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34–43CrossRefPubMedGoogle Scholar
  3. 3.
    Cantu MG, Buda A, Parma G et al. (2002) Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 20: 1232–1237CrossRefPubMedGoogle Scholar
  4. 4.
    Citron ML, Berry DA, Cirrincione C et al. (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21: 1431–1439CrossRefPubMedGoogle Scholar
  5. 5.
    du Bois A, Lück HJ, Meier W et al. (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 3: 1320–1329Google Scholar
  6. 6.
    du Bois A, Combe M, Rochon J et al. (2004) Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer (OC) FIGO stages IIB–IV. An AGO-GINECO Intergroup phase III trial. J Clin Oncol 22 (suppl): 5007Google Scholar
  7. 7.
    du Bois, Quinn M, Thigpen T et al. (2005) 2004 Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 16 (suppl 8): viii7–viii12CrossRefPubMedGoogle Scholar
  8. 8.
    Gadducci A, Carnini F, Chiara S et al. (2000) Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologica Nord-Ovest. Gynecol Oncol 76: 157–162CrossRefPubMedGoogle Scholar
  9. 9.
    Gonzalez-Martin AJ, Calvo E, Bover I et al. (2005) Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol 16: 749–755CrossRefPubMedGoogle Scholar
  10. 10.
    Gordon AN, Tonda M, Sun S et al. (2004) Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95: 1–8CrossRefPubMedGoogle Scholar
  11. 11.
    Gore M, Oza A, Rustin G et al. (2002) A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer 38: 57–63CrossRefPubMedGoogle Scholar
  12. 12.
    Guyatt GH, Sackett DL, Cook DJ for the Evidence-Based Medicine Working Group (1993) Users‘ guides to the medical literature, II. How to use an article about a therapy or prevention. A. Are the results of the study valid? JAMA 270: 2598–2601CrossRefPubMedGoogle Scholar
  13. 13.
    ICON and AGO Collaborators (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361: 2099–2106CrossRefPubMedGoogle Scholar
  14. 14.
    Jaaback K, Johnson N (2006) Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer .Cochrane Database Syst Rev CD005340Google Scholar
  15. 15.
    Kirmani S, Braly PS, McClay EF et al. (1994) A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol Oncol 54: 338–344CrossRefPubMedGoogle Scholar
  16. 16.
    Markman M, Bundy BN, Alberts DS et al. (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19: 1001–1007PubMedGoogle Scholar
  17. 17.
    Markman M, Hall J, Spitz D et al. (2002) Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 20: 2365–2369CrossRefPubMedGoogle Scholar
  18. 18.
    Ozols RF, Bundy BN, Greer BE et al. (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21: 3194–3200CrossRefPubMedGoogle Scholar
  19. 19.
    Pfisterer J, Weber B, du Bois A et al. (2005) Paclitaxel/Carboplatin (TC) vs. Paclitaxel/Carboplatin followed by Topotecan (TOP) in first-line treatment of advanced ovarian cancer. Mature results of a gynecologic cancer intergroup phase III trial of the AGO OVAR and GINECO. J Clin Oncol 23 (suppl): 456s (LBA5007)Google Scholar
  20. 20.
    Polyzos A, Tasvaris N, Kosmas C et al. (1999) A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology 56: 291–296CrossRefPubMedGoogle Scholar
  21. 21.
    Thigpen T, Stuart G, du Bois A et al. (2005) Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens. Ann Oncol 16 (suppl 8): viii13–viii19CrossRefPubMedGoogle Scholar
  22. 22.
    Yen MS, Juang CM, Lai CR et al. (2001) Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int J Gynecol Obstet 72: 55–60CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag 2006

Authors and Affiliations

  • A. du Bois
    • 1
  • B. Schmalfeldt
    • 1
  • W. Meier
    • 1
  • J. Sehouli
    • 1
  • J. Pfisterer
    • 1
  • die AGO Studiengruppe Ovarialkarzinom (AGO-OVAR) und die Nordostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO)
  1. 1.Klinik für Gynäkologie und Geburtshilfe Campus KielUniversitätsklinikum Schleswig-HolsteinKiel

Personalised recommendations